Praesidia combines the Antibody Drug Conjugation strategy (7 new ADCs approved and strategic deals over $20B in last 2 years) with its BBB Crossing Linkers to address key unmet clinical need of brain cancer. With proof-of-concept of strategy established, Praesidia is raising funding to develop drug candidates to IND and Phase 1 clinical stage. Founding team of successful entrepreneurs and eminent scientists would ensure a successful exit.